TCS Launches Agentic AI Platform to Advance Drug Development

The platform supports a range of clinical and pharmacovigilance activities, including individual case safety report intake, data entry, coding, etc.

Tata Consultancy Services (TCS) has launched TCS ADD AgentHub, an enterprise-ready agentic AI platform aimed at supporting pharmaceutical companies in deploying AI across drug development and drug safety processes.

The platform seeks to address the challenges faced by pharma companies in scaling AI across drug development due to growing data volumes, fragmented technology systems, and evolving regulatory requirements.

Agent Hub is designed to provide a structured framework in which AI agents operate within defined roles while maintaining human oversight and meeting regulatory and audit requirements.

Built on the TCS ADD framework, the platform allows pharmaceutical companies to customise their AI agent hubs and deploy them across clinical workflows with minimal integration and implementation effort.

The platform supports a range of clinical and pharmacovigilance activities, including individual case safety report intake, data entry, coding, review, literature analysis, study design, protocol digitisation, clinical data review and SDTM transformation.

Additionally, it assists in medical monitoring. TCS said AgentHub enables a Human + AI Operating Model, where AI agents work within enterprise processes while humans retain responsibility for governance and decision-making.

By standardizing how AI agents are deployed across these processes, the platform seeks to help organizations improve productivity and focus scientific teams on higher‑value work.

The company stated that the solutions powered by the platform have demonstrated up to 40% efficiency gains in clinical data management activities, up to 30% reduction in clinical study build effort through metadata-driven automation, and up to 30% cost savings in end-to-end safety case processing.

In addition, the company reported that AI-powered safety agents can reduce quality control effort by as much as 50%, helping organizations improve productivity across critical R&D processes.

Commenting on the latest technology, Debashis Ghosh, President, Life Sciences and Healthcare, TCS, said, “TCS ADD AgentHub is a role-based, enterprise-ready, and trusted AI platform that will enable our customers to accelerate drug development using agentic AI at scale. It enables a shift from reactive to proactive, scalable, and audit-ready operations amidst an ever-changing regulatory environment.”

“TCS’ strategy is to move towards autonomous enterprise functions where an AI agentic workforce operates alongside humans, driving innovation in drug development and improving patient safety,” he added

Stay tuned for more such updates on Digital Health News